Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic in adults. Patient management is dependent upon physician judgment and patient preference, given both the rarity of the condition and a paucity of high-quality clinical trial evidence to inform practice guidelines. A systematic literature review was conducted to provide an up-todate summary of studies evaluating the safety and efficacy/effectiveness of therapies used to treat adults with primary ITP in the second-line setting. Using comprehensive search strings, several medical research databases were queried. Final abstraction was performed on 186 articles. Most (75%) studies were observational in nature; nearly half were conducted in Europe.
>16 years, had ITP for >3 months, and a platelet count <50 × 10 9 /L. 12 Only one study 13 was a randomized controlled trial (RCT) but the randomization was by dose of the same therapy; the remaining were cohort studies or uncontrolled case series. A complete response (as defined in each respective original report) was achieved in 14% of patients across the 22 treatment types, with the largest numbers of responders reported with cyclophosphamide (27% of 83 patients), rituximab (24% of 41 patients), and azathioprine (17% of 109 patients). Although partial response was achieved in 40% of patients across these three therapies, 36% to 42% had no response. This review focused on the third-line setting and beyond, but it demonstrated that at least at that time, there was minimal evidence for the effectiveness of any medical treatment for ITP patients with persistent, severe thrombocytopenia, highlighting the need for RCTs to properly evaluate potentially effective treatments in this setting.
Since the publication of this systematic review, the management of ITP has evolved. Treatment decisions are less likely to be guided solely by platelet counts and more likely to rely on a combination of platelet levels;
shared decision making between the physician and the patient; and patient factors, such as insurance coverage, lifestyle, history of bleeding, occupation, comorbidities, and expectations. 9 Thrombopoietin-receptor agonists (TPO-RAs), including eltrombopag and romiplostim, have also entered the market after undergoing rigorous randomized trials in splenectomized and non-splenectomized patients with persistent or chronic ITP. [14] [15] [16] Additionally, the incidence of splenectomy has declined in recent years. 17, 18 Despite these developments and trends, the International Consensus
Report on the management of primary ITP (released in 2010) lists medical treatment options in the second-line setting in alphabetical order to avoid indicating a preference for a specific treatment, highlighting the lack of sufficient data to rank the treatments according to efficacy. 1 Similarly, shortly after the publication of this report, the American Society of Hematology (ASH) published practice guidelines for ITP, concluding that there is no evidence to guide a sequence of treatment for patients who have recurrent or persistent thrombocytopenia with bleeding after first-line treatment with corticosteroids, IVIg, or anti-D. 19 Indeed, clinical decision-making on optimal second-line ITP treatment is challenging and has been described as controversial. 20, 21 The lack of prescriptive clinical guidance in this setting highlights a gap in the scientific literature regarding comparisons of safety and efficacy across available treatments. 2, 22 Given this and the changing treatment landscape over the past decade, we sought to systematically review published reports and provide an up-to-date summary of studies evaluating the safety and efficacy/effectiveness of therapies used to treat primary ITP in adults in the second-line setting, with a particular focus on RCTs that have been conducted.
| METHODS
The scope of this review included both interventional and observational studies that evaluated the safety, efficacy (from interventional designs), and/or effectiveness (from observational designs) of therapies used to treat primary ITP in adults in the second-line setting. We excluded studies in which the therapy of interest was used in the first-line setting, case series with less than 20 patients, studies published in languages other than English, and studies conducted in children, pregnant women, or patients with secondary thrombocytopenia. Table 1 ). Bibliographies of relevant reviews and metaanalyses were also searched for additional pertinent publications. The flow diagram of study inclusion is presented in Figure 1 . Study citations were downloaded into a database, and duplicates were removed from the search results using automated de-duplication methods and manual screening. Studies were reviewed for relevance at the levels of title, abstract, and full text by two independent reviewers. Articles designated as eligible for inclusion were abstracted into a database and independent reviewers performed a quality control assessment for accuracy on each abstracted study. Disagreements were resolved by consensus adjudication. If more than one article from the same study population was published, data from the publication with the longest follow-up, most recent data, and/or most specifically relevant population and/or outcomes were extracted. Data elements abstracted included study design, population characteristics, treatment description and dosage, and the aforementioned efficacy/effectiveness and safety outcomes. Several measures to assess study bias were also abstracted using the Cochrane Risk of Bias Tool, 24 including evaluation of randomization, concealment, blinding, baseline comparability, follow-up, selective reporting, and analysis.
Tabulated summaries were generated to explain basic characteristics of the included studies. Results for placebo-controlled RCTs or standardof-care (SOC)-controlled RCTs were examined in detail, given their general comparability in trial design and rigor. For these studies, for endpoints/outcomes common to at least two studies (complete platelet response, overall platelet response, use of rescue therapies, and bleeding), the study definition of that endpoint and the corresponding results were described. Rate ratios and response ratios and 95% confidence intervals (CIs) were calculated to compare rate/response of the outcome of interest in patients receiving the therapy of interest and patients receiving placebo or SOC for each outcome from each study. Forest plots for each endpoint/outcome were created to display the risk/ response ratios across individual studies and therapies. In addition to the measures that were formally described in rate/response ratios and forest plots, median duration of overall/complete platelet response from each study was collected and described, when available. Analyses were performed using R statistical software 25 and the "metafor" package. 26 A formal meta-analysis was not performed due to the small number of studies for some treatments (n < 3).
| RESULTS
Of nearly 300 000 publications identified through our comprehensive literature searches, 186 reports met our inclusion criteria of studies evaluating the safety and efficacy/effectiveness of the second-line therapies of interest in adult primary ITP. An overview of the basic characteristics of these studies is summarized in Table 1 .
The majority (N = 139; 75%) of studies were observational in nature, FIGURE 1 Flowchart of article selection for the systematic literature review. Comprehensive search strings were applied to the medical research databases, and studies were reviewed for relevancy at the levels of title, abstract, and full text. [Color figure can be viewed at wileyonlinelibrary.com]
with retrospective cohort studies being the most common (N = 104; 56% of total), followed by prospective cohort studies (N = 32; 17% of total). A substantial proportion (47%) of the studies were conducted solely in European countries, 14% were based on United States (US) data alone, 12% were based on data from China and Japan alone, and 3% were conducted solely in Australia. Of the therapies included in our search, splenectomy was the most commonly studied (N = 83; 47%), followed by rituximab (N = 49; 26%), romiplostim (N = 34; 18%), and eltrombopag (N = 24; 13%). All other therapies were the focus of just 1% to 4% of the studies identified, and just over 4% of the studies included a combination of at least two of the therapies of interest.
For most of the treatments, including azathioprine, cyclophosphamide, cyclosporine, danazol, dapsone, mycophenolate mofetil, vinblastine, and vincristine, there were limited studies of efficacy/ effectiveness and safety identified. Only 22 unique studies conducted over the past four decades covered at least one of these eight therapies, the majority (n = 16) of which were observational in nature. Of note, cyclophosphamide and vincristine have not been studied in a prospective, interventional manner, and the remaining 6 therapies are supported by one such study each. However, the sole interventional study of cyclosporine evaluated this therapy in combination with oral dexamethasone and IV low-dose rituximab in a phase 2b study. 27 The other five studies are briefly described here.
In a single-arm study of 53 adults with chronic ITP treated with azathioprine, 45% of patients had a "complete remission" after receiving azathioprine (defined as platelet counts ≥150 × 10 9 /L for at least 3 months); median time to response was 4 months. 28 In Table 2 , and study-specific definitions of the outcomes/endpoints common to at least two of the studies are provided in Table 3 . Two studies were prospective phase ).
All 12 RCTs reported on some measure of overall platelet response, with studies of TPO-RAs using a definition centered on a platelet count threshold of ≥50 × 10 9 /L and rituximab studies utilizing a lower threshold of ≥30 × 10 9 /L (Table 3 ). Across TPO-RA studies, which enrolled both splenectomized and non-splenectomized patients, the overall platelet response tended to be higher in patients receiving eltrombopag or romiplostim compared with patients in the respective placebo/SOC arms ( Figure 2 /L) over a specified period of time (Table 3) . Across all three treatments evaluated, response rates tended to be higher in patients receiving one of the treatments vs those in patients receiving placebo or SOC (Figure 3 ). Similar to the data around overall platelet response, the differences in complete platelet response between treated and placebo/SOC patients were greatest among studies of eltrombopag (rate ratios ranging from 4. Duration of response during the active, blinded treatment period was reported in three of the 12 RCTs (Table 3) . 33, 37, 40 In a trial of eltrombopag administered daily for 6 months, the maximum continuous response was a median of 8.1 weeks among eltrombopag patients and 0 weeks among placebo patients. 33, 41 A study of rituximab examined the median time to relapse after achieving overall or complete platelet response following four weekly infusions of rituximab. (Table 3 ). In general, bleeding rates in patients 
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Both rituximab trials that reported rates of bleeding were conducted in non-splenectomized patients and observed slightly lower but similar bleeding rates between patients receiving rituximab and placebo 36, 37 ( Figure 5 ).
No studies represented prospective RCTs with splenectomy and a placebo or SOC arm, but surgical splenectomy has been well-studied and still represents an important treatment option for ITP patients in the second-line setting. Among the 83 studies evaluating splenectomy, the reported rates of complete response rates ranged from 37.3% 42 to 100% 43 with a median complete response rate of 70.5% across studies. The median partial response rate was 13.5% (range FIGURE 3 Complete platelet response in trials of eltrombopag, rituximab, or romiplostim. Calculated response ratios comparing the complete platelet response of patients receiving eltrombopag, rituximab, or romiplostim vs that in patients receiving placebo or standard of care FIGURE 4 Rescue therapy use in trials of eltrombopag, rituximab, or romiplostim. Calculated rate ratios comparing the rate of rescue therapy use among patients receiving eltrombopag, rituximab, or romiplostim vs that in patients receiving placebo or standard of care ). Mortality rates ranged from 0% among multiple studies to 28.8% 56 (over a median follow-up time of 18 years) (median 2% across studies).
| DISCUSSION
This systematic review identified published reports of interventional and observational studies that have evaluated the efficacy/effectiveness and safety of therapies used to treat adults with primary ITP in the second-line setting. All therapies of interest were represented in the studies identified, and the majority of studies were observational (and primarily retrospective) in nature.
For the majority of non-surgical treatments, including azathioprine, cyclophosphamide, cyclosporine, danazol, dapsone, mycophenolate mofetil, vinblastine, and vincristine, there were limited published reports of any kind. Just over 11% of all 186 reports meeting our inclusion criteria focused on at least one of these agents, and only 5 studies (<3% of total) investigated one of these agents as a monotherapy in a prospective, interventional manner. Of note, four of these studies were conducted over two decades ago. Therefore, it is not surprising that although these agents may have promise in treat- ing and infrequent need for rescue therapy. 57 Most patients (63%) FIGURE 5 Bleeding in trials of eltrombopag, rituximab, or romiplostim. Calculated rate ratios comparing the rate of bleeding in patients receiving eltrombopag, rituximab, or romiplostim vs that in patients receiving placebo or standard of care responded after just one dose of romiplostim, and the proportion of patients with a platelet ≥50 × 10 9 /L remained between 62% and 78% through week 212. Eltrombopag and romiplostim are both agents that interact with the TPO receptor to trigger platelet production and are indicated for the treatment of thrombocytopenia in the second-line setting and beyond in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. [59] [60] [61] [62] Results from the two rituximab studies, which were both conducted exclusively in non-splenectomized patients, provided less conclusive results. 36, 37 In after the first infusion without additional ITP treatment. 57 After a median follow-up of 3.8 years, 64% of these adults maintained their response to rituximab. Authors used these data, in combination with data from published reports, to estimate that the 1-year and 5-year response rates for adults treated with rituximab are 38% and 21%, respectively. Importantly, rituximab, an anti-CD20 antibody, is currently not approved for the treatment of ITP but is widely used in this setting. 63 However, as Ghanima et al. 37 point out, their placebocontrolled study of rituximab emphasizes the need for additional RCTs to assess the efficacy and safety of treatment in this setting before implementation and cautions against relying on evidence from uncontrolled studies.
Although not formally studied as a treatment arm in any prospective RCT, splenectomy is widely covered in the literature. Importantly, it is still generally recommended as the standard therapy for patients with chronic ITP, given the high probability of durable platelet response. 1, 11, 19 However, this invasive surgical procedure is not without risk; perioperative and short-term and long-term postoperative complications, such as infections, thromboembolic events, and increased risk of certain malignancies including buccal, esophageal, colon, liver, pancreatic, lung, prostate, and hematopoietic cancers have been observed. 64, 65 Additionally, there is currently no ability to reliably predict who will respond, and there is evidence that a portion of non-splenectomized patients will experience late remissions either spontaneously or with continuing medical treatment. 22, 66, 67 Due to these issues and because of the availability of medical alternatives, splenectomy may not be the "go-to" treatment it once was for patients requiring second-line therapy, 21 as evidenced by recent temporal trends in the uptake of splenectomy. 17, 18 For example, in a study conducted in Denmark, the 1-year cumulative incidence of splenectomy among patients with ITP for a duration of at least 6 months decreased in recent years, from 10% for those diagnosed in 1996 through 2001 to 3% for those diagnosed in 2008 through 2012. 18 With fewer patients undergoing splenectomy in the second-line setting, there is a need to further investigate the potential for medical treatments to delay or obviate the need for splenectomy.
Drawing specific treatment recommendations from this review is challenging. There was a paucity of data for several of the therapies of interest, namely azathioprine, cyclophosphamide, danazol, dapsone, mycophenolate mofetil, and vinca alkaloids, making it difficult to assess the relative value of these treatments in this setting. Small sample size and rarity of events also resulted in a lack of precision for some outcomes. Additionally, comparability of data across the studies was somewhat limited by a lack of consistency in the outcomes measured and varying outcome definitions. Although recommendations on standard terminology, definitions, and outcome criteria in ITP were developed by an International Working Group nearly a decade ago, 68 they have not been widely adopted, even in the clinical trial setting. Ideally, more randomized and controlled clinical studies would be conducted to properly assess the risk: benefit profile of any existing or new treatment by itself or against other options in this setting.
Alternatively, given the rarity of both ITP and any potential adverse events associated with a given therapy, well-designed noninterventional studies using large population-based sources of data, such as those from administrative claims databases, electronic health record databases, or disease-specific or treatment-specific registries, could offer valuable evidence on the real-world effectiveness and safety and comparative effectiveness and safety of available treatments. 72 In the absence of such studies, clinical expertise, patient preference and shared decision making will continue to be the primary drivers of treatment decisions rather than high-quality clinical trial evidence or robust observational studies.
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